Search Medical Condition
Please enter condition
Please choose location from dropdown

Angers Cedex 2, France Clinical Trials

A listing of Angers Cedex 2, France clinical trials actively recruiting patients volunteers.

Found (366) clinical trials

SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013

Topotecan is currently the only drug approved in Europe and the United States for the treatment of second line of SCLC when the recovery first line of treatment is considered inappropriate. This raises the problem of knowing when the recovery first line of treatment should be considered appropriate. Secondly, the …

Phase

0.0 miles

Learn More »

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

Post operative chemotherapy +/- radiotherapy according to histopathological risk factors of the International Retinoblastoma Staging Working Group. Low risk group : No optic nerve involvement. Intra and prelaminar involvement No choroidal involvement. Minimal superficial choroidal involvement . Intermediate risk group, 2 sub groups : Sub group 1 : Retrolaminar involvement …

Phase

0.0 miles

Learn More »

Comparison of Gastric By-Pass and Optimized Medical Treatment in Obese Diabetic Patients

Optimizing the management of type 2 diabetes (T2D) will remain a major public health concern for decades to come. T2DM has already affected 4% of the French population and generates each year over 12 billion euros of expenditure. By combining therapies, oral and/or injectable (insulin or analogues of GLP-1), the …

Phase

0.0 miles

Learn More »

Impact of DietarY and LIfestyle Risk Factors on Colorectal Cancer Screening

Background: The clinical value of early detection of colorectal cancer has been clearly demonstrated. The evaluation in 23 pilot counties of the organized screening program for colorectal cancer in France, that was widespread throughout the country in 2009, concluded that results are satisfactory but should be improved especially in terms …

Phase N/A

0.0 miles

Learn More »

National Register of Oesophageal Atresia

The esophageal atresia is a group of birth defects including a break in continuity of the esophagus with or without persistent communication with the trachea (tracheoesophageal fistula), sometimes associated (from 50%) of other malformations (heart, kidney, digestive ...). The current prognosis for this ailment is good. However he persists a …

Phase N/A

0.0 miles

Learn More »

This research study will look at how effective niraparib (a PARP inhibitor) is compared to placebo (a pill with no medicine in it, like a sugar pill) in maintenance therapy for women who have ovarian, fallopian tube or peritoneal cancer, and have responded (complete or partial response) to front-line platinum-based …

Phase

0.0 miles

Learn More »

Mucormycosis in ICU

Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. The incidence of Mucormycosis is currently increasing reaching 7% of invasive fungal infections in some immunocompromised patients. Because of its aggressive nature, Mucormycosis is associated with …

Phase N/A

0.0 miles

Learn More »

Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma

Current limitations in the management of high grade brain tumors partly reside in the lack of access to pathological tissue. Conventional biopsy devices can cause severe side effects, thus limiting the amount of tissue that can be collected for molecular characterization. The Brain-Tissue-Imprint Devices evaluated in this trial offers a …

Phase N/A

0.0 miles

Learn More »

Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers

The aflibercept-5-FU combination has never been evaluated as yet. Aflibercept, at a dose of 4 mg/kg, has already been used in combination with 5-FU at the doses used in the simplified LV5FU2 regimen (folinic acid 400 mg/m2 IV in 90 min, then 5-FU 400 mg/m2 IV bolus on D1, followed …

Phase

0.0 miles

Learn More »

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary …

Phase

0.0 miles

Learn More »